← Leaderboards
Amit Verma
Albert Einstein Col Of Med Yeshiva Univ
$10,906,014
Attributed
$19,426,651
Total exposure
13
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,710,646 · 9
CDC$3,716,005 · 4
By mechanism
R01$13,510,759 · 7
U01$3,433,708 · 3
K12$2,199,887 · 2
R21$282,297 · 1
Top collaborators
- Ulrich Steidl9 shared
- Marina Y Konopleva5 shared
- David J Prezant5 shared
- Stefano Tiziani5 shared
- Daniel Starczynowski4 shared
- Amittha Wickrema4 shared
- Yvonne Margaret Saenger3 shared
- Michael R Savona3 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsDysmyelopoietic SyndromesIn VitroTherapeutic TargetPathway InteractionsMolecularStem CellsOverexpressionXenograft ProcedureSamplingIn VivoMediatingClinically RelevantGrowthStemLeukemiaMarrowInhibitor/AntagonistResponseHematopoietic NeoplasmsMouse ModelSignal PathwayHematopoieticLead
Grant awards (44)
Montefiore Einstein Clinical Oncology Training Program in the Bronx$691,824
K12 · FY2025 · CA · contact PI
Therapeutic targeting of IRAK4 in MDS$528,024
R01 · FY2025 · CA · contact PI
Blood mutations and cancer associations among WTC-exposed Firefighters$282,297
R21 · FY2025 · OH · contact PI
Diversity-focused Montefiore Einstein Clinical Oncology Training Program in the Bronx$707,995
K12 · FY2024 · CA · contact PI
Therapeutic targeting of IRAK4 in MDS$501,623
R01 · FY2024 · CA · contact PI
Therapeutic targeting of IRAK4 in MDS$517,464
R01 · FY2023 · CA · contact PI
EARLY DETECTION OF CLONAL HEMATOPOIESIS AND LEUKEMIA ASSOCIATED MUTATIONS IN WTC EXPOSED FIREFIGHTERS AFTER THE 9/11 ATTACKS$488,632
U01 · FY2023 · OH · contact PI
Diversity-focused Montefiore Einstein Clinical Oncology Training Program in the Bronx$25,661
K12 · FY2023 · CA · contact PI
Therapeutic targeting of IRAK4 in MDS$545,024
R01 · FY2022 · CA · contact PI
STAT3 inhibition as a therapeutic strategy against MDS stem cells$531,973
R01 · FY2022 · HL · contact PI
EARLY DETECTION OF CLONAL HEMATOPOIESIS AND LEUKEMIA ASSOCIATED MUTATIONS IN WTC EXPOSED FIREFIGHTERS AFTER THE 9/11 ATTACKS$488,632
U01 · FY2022 · OH · contact PI
STAT3 inhibition as a therapeutic strategy against MDS stem cells$531,973
R01 · FY2021 · HL · contact PI
Therapeutic targeting of MDS stem cells$528,896
R01 · FY2021 · HL · contact PI
EARLY DETECTION OF CLONAL HEMATOPOIESIS AND LEUKEMIA ASSOCIATED MUTATIONS IN WTC EXPOSED FIREFIGHTERS AFTER THE 9/11 ATTACKS$488,696
U01 · FY2021 · OH · contact PI
STAT3 inhibition as a therapeutic strategy against MDS stem cells$531,973
R01 · FY2020 · HL · contact PI
Therapeutic targeting of MDS stem cells$528,896
R01 · FY2020 · HL · contact PI
Therapeutic targeting of glutamine metabolism in MDS$481,538
R01 · FY2020 · CA
Paul Calabresi Career Development Award for Clinical Oncology (K12)$774,407
K12 · FY2019 · CA
STAT3 inhibition as a therapeutic strategy against MDS stem cells$531,973
R01 · FY2019 · HL · contact PI
Therapeutic targeting of MDS stem cells$528,896
R01 · FY2019 · HL · contact PI
Cooperative Research Agreements Related to the World Trade Center Health Program (U01)$499,807
U01 · FY2019 · OH · contact PI
Cooperative Research Agreements Related to the World Trade Center Health Program (U01)$468,270
U01 · FY2019 · OH · contact PI
Therapeutic targeting of glutamine metabolism in MDS$467,092
R01 · FY2019 · CA
Early Detection of Hematologic Malignancies in New York City Firefighters Exposed To World Trade Center Dust After The 9/11 Attacks$499,807
U01 · FY2018 · OH · contact PI
Therapeutic targeting of glutamine metabolism in MDS$496,810
R01 · FY2018 · CA
Therapeutic targeting of MDS stem cells$359,976
R01 · FY2018 · HL · contact PI
Therapeutic targeting of MDS stem cells$168,920
R01 · FY2018 · HL · contact PI
Early Detection of Hematologic Malignancies in New York City Firefighters Exposed To World Trade Center Dust After The 9/11 Attacks$499,864
U01 · FY2017 · OH · contact PI
Therapeutic targeting of glutamine metabolism in MDS$474,750
R01 · FY2017 · CA
Therapeutic targeting of MicroRNA-21 in Myelodysplastic syndromes$358,005
R01 · FY2017 · DK · contact PI
Therapeutic targeting of glutamine metabolism in MDS$506,879
R01 · FY2016 · CA
Therapeutic targeting of MicroRNA-21 in Myelodysplastic syndromes$358,005
R01 · FY2016 · DK · contact PI
The role of Dock4 in normal and aberrant erythropoiesis$400,155
R01 · FY2015 · HL
Therapeutic targeting of MicroRNA-21 in Myelodysplastic syndromes$268,503
R01 · FY2015 · DK · contact PI
Therapeutic targeting of MicroRNA-21 in Myelodysplastic syndromes$89,502
R01 · FY2015 · DK · contact PI
The role of Dock4 in normal and aberrant erythropoiesis$398,125
R01 · FY2014 · HL
Therapeutic targeting of MicroRNA-21 in Myelodysplastic syndromes$374,973
R01 · FY2014 · DK · contact PI
The role of Dock4 in normal and aberrant erythropoiesis$386,750
R01 · FY2013 · HL
The role of Dock4 in normal and aberrant erythropoiesis$420,750
R01 · FY2012 · HL
p38 MAPK as a therapeutic target in Myelodysplastic syndrome$111,851
R01 · FY2009 · HL · contact PI
p38 MAPK as a therapeutic target in Myelodysplastic syndrome$383,539
R01 · FY2008 · HL · contact PI
p38 MAPK as a therapeutic target in Myelodysplastic syndrome$383,539
R01 · FY2007 · HL · contact PI
p38 MAPK as a therapeutic target in Myelodysplastic syn*$394,994
R01 · FY2006 · HL · contact PI
p38 MAPK--Therapeutic target in Myelodysplastic syndrome$419,388
R01 · FY2005 · HL